KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $1.6 billion.

  • Pacira BioSciences' Liabilities and Shareholders Equity fell 14.73% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year decrease of 5.55%. This contributed to the annual value of $1.6 billion for FY2024, which is 1.33% down from last year.
  • As of FY2024, Pacira BioSciences' Liabilities and Shareholders Equity stood at $1.6 billion, which was down 1.33% from $1.6 billion recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Liabilities and Shareholders Equity ranged from a high of $2.1 billion in FY2021 and a low of $1.3 billion during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.6 billion (2023), whereas its average is $1.6 billion.
  • As far as peak fluctuations go, Pacira BioSciences' Liabilities and Shareholders Equity spiked by 62.83% in 2021, and later declined by 18.99% in 2022.
  • Yearly analysis of 5 years shows Pacira BioSciences' Liabilities and Shareholders Equity stood at $1.3 billion in 2020, then spiked by 62.83% to $2.1 billion in 2021, then declined by 18.99% to $1.7 billion in 2022, then fell by 6.35% to $1.6 billion in 2023, then fell by 1.33% to $1.6 billion in 2024.